Drugs / NCR101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06825169 | Mar 2025 → Mar 2026 overdue | interstitial lung disease | Nuwacell Biotechnologies Co., Ltd. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-10-24 | Nuwacell Biotechnologies Co., Ltd. | Results 中盛溯源荣登“2025中国医药创新种子企业100强” nuwacell.com ↗
临床数据显示，患者用力肺活量（FVC）提升20.2％，肺总容量增加，肺部磨玻璃影消失，部分患者还出现白发转黑、可进行中等强度健身活动等全身性机能改善。 |
| 2025-09-02 | Nuwacell Biotechnologies Co., Ltd. | Results 肺里的「云雾」散了！中盛溯源 NCR101 见证从有到无的医学奇迹 nuwacell.com ↗
输注后 8 周观察到用力肺活量（FVC）提高 20.2%，其他药效指标 HRCT 评分、圣乔治呼吸系统问卷评估（SGRQ）、6 分钟步行试验距离均值较基线均有明显的改善。 |
| 2025-03-13 | Nuwacell Biotechnologies Co., Ltd. | Regulatory iPSC新突破！中盛溯源全球首个基因修饰iMSC获批临床！ nuwacell.com ↗ |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-10-24 | Nuwacell Biotechnologies Co., Ltd. | 中盛溯源荣登“2025中国医药创新种子企业100强” nuwacell.com ↗ |
| 2025-09-02 | Nuwacell Biotechnologies Co., Ltd. | 肺里的「云雾」散了！中盛溯源 NCR101 见证从有到无的医学奇迹 nuwacell.com ↗ |
| 2025-03-13 | Nuwacell Biotechnologies Co., Ltd. | iPSC新突破！中盛溯源全球首个基因修饰iMSC获批临床！ nuwacell.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NCR101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06825169 ↗ |
| Modality | Cell therapy | “Human Induced Pluripotent Stem Cell Derived Mesenchymal Stromal Cells (NCR101) Injection” NCT06825169 ↗ |